Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma and Metastatic Uveal Melanoma

NCT02831933 is registered in ClinicalTrials.gov with Eric Bernicker, MD as lead sponsor.

NCT NCT02831933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02831933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma and Metastatic Uveal Melanoma
Lead sponsor
Eric Bernicker, MD
Phase
Phase 2
Overall status
Terminated
Start date
February 15, 2017
Completion date
November 5, 2020
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung squamous cell carcinoma stage iv, metastatic uveal melanoma, nonsquamous nonsmall cell neoplasm of lung